T
Translate Bio
Developing mRNA medicines to restore protein function
At a glance
- Founded
- 2011
- Headquarters
- Cambridge, United States
- Listing
- IPO 2018
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tierThoroughbred$100M+ revenue
Latest news
Press, funding announcements and product moves mentioning Translate Bio.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
- OFOmega Funds
- SOSR One
Atlas Venture- MVM Ventures
- PFPartners Innovation Fund
Series B and later6 investors entered at this stage
- RCRock Springs Capital
- MTMassachusetts Institute of Technology
- BCBrookside Capital
- PFPfizer
- TCTransformation Capital
- MVMonsanto Growth Ventures
Source: Dealroom Talent Intelligence.
Alumni founders
Former Translate Bio employees who went on to found companies, sorted by Dealroom signal score.
STSpero TherapeuticsEst. 2013
Ankit MahadeviaUnited States
FTFulcrum TherapeuticsEst. 2016
Jeannie T. LeeUnited States
CBCodiak BiosciencesEst. 2015
Phillip SamayoaUnited States
VBVernal BiosciencesEst. 2021
Christian CobaughUnited StatesGlobal footprint
Patents
153 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Translate Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Translate Bio on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.